Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

doi:10.3748/wjg.v28.i45.6380

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 45

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5121)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

292

WORD

HTML

2609

Figures (1-1)

443

Tables (1-7)

425

Sum=3849

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

400

Download

872

Sum=1272

Dec 7, 2022 (publication date) through Mar 31, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Dec 7, 2022; 28(45): 6380-6396
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6380

Table 4 The overall treatment effectiveness and according to treatment regimens in relation to different risk factors among the studied patients (per protocol analysis)

Parameter	Whole population	Females	Males	F4	T-ex	History of hepatic decompensation	≥ 70-year-old	eGFR ≤ 60 mL/min	Obese¹	HIV+
All regimens	10903/11112 (98.1)	5891/5969 (98.7)	5012/5143 (97.5)	2590/2678 (96.7)	2726/2795 (97.5)	319/336 (94.9)	1490/1509 (98.7)	281/284 (98.9)	1880/1923 (97.8)	327/341 (95.9)
ASV + DCV	119/132 (90.2)	72/79 (91.1)	47/53 (88.7)	47/55 (85.5)	40/47 (85.1)	0/1 (0)	22/24 (91.7)	5/5 (100)	26/28 (92.9)	1/1 (100)
LDV/SOF ± RBV	2534/2582 (98.1)	1381/1398 (98.8)	1153/1184 (97.4)	679/707 (96)	680/696 (97.7)	173/181 (95.6)	386/389 (99.2)	67/67 (100)	446/459 (97.2)	103/107 (96.3)
OBV/PTV/r + DSV ± RBV	3563/3627 (98.2)	1949/1973 (98.8)	1614/1654 (97.6)	969/992 (97.7)	1490/1516 (98.3)	72/74 (97.3)	397/403 (98.5)	80/82 (97.6)	602/611 (98.5)	26/28 (92.9)
GZR/EBR ± RBV	2179/2216 (98.3)	1201/1215 (98.8)	978/1001 (97.7)	362/372 (97.3)	291/297 (98)	19/20 (95)	397/401 (99)	87/88 (98.9)	380/389 (97.7)	48/48 (100)
GLE/PIB	1625/1643 (98.9)	869/874 (99.4)	756/769 (98.3)	264/268 (98.5)	112/114 (98.2)	12/12 (100)	147/150 (98)	24/24 (100)	267/267 (100)	72/76 (94.7)
GLE/PIB + SOF + RBV	3/3 (100)	1/1 (100)	2/2 (100)	1/1 (100)	3/3 (100)	-	-	-	1/1 (100)	-
SOF/VEL ± RBV	857/884 (96.9)	409/419 (97.6)	448/465 (96.3)	260/275 (94.5)	91/101 (90.1)	40/44 (90.9)	138/139 (99.3)	16/16 (100)	158/167 (94.6)	74/78 (94.9)
VOX/VEL/SOF	9/9 (100)	2/2 (100)	7/7 (100)	3/3 (100)	7/7 (100)	-	3/3 (100)	-	-	3/3 (100)

¹Body mass index > 30 kg/m².

Data are presented as number/total number of patients (percentage). ASV: Asunaprevir; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; eGFR: Estimated glomerular filtration rate; F: Fibrosis; GLE: Glecaprevir; GZR: Grazoprevir; HIV: Human immunodeficiency virus; LDV: Ledipasvir; OBV: Ombitasvir; PIB: Pibrentasvir; PP: Per protocol; PTV/r: Paritaprevir; RBV: Ribavirin; SOF: Sofosbuvir; SVR: Sustained virological response; T-ex: Treatment-experience; VEL: Velpatasvir; VOX: Voxilaprevir.

Citation: Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol 2022; 28(45): 6380-6396
URL: https://www.wjgnet.com/1007-9327/full/v28/i45/6380.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i45.6380